AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12452021
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy alone
Trial: 12452021
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (HDT combined with ASCT)
Trial: 8461508
Drug: Nitroglycerin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (1 microgram/kg per min, low dose)
Trial: 8461508
Drug: Nitroglycerin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (2 micrograms/kg per min, high dose)
Trial: 3954933
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of amoxycillin as a single i.v. infusion
Trial: 3954933
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of ampicillin as a single i.v. infusion
Trial: 30328302
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser plus Sodium Fluoride (L+NaF)
Trial: 30328302
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments (CPP-ACPF, HA-NaF-X, L+CPP-ACPF, L+HA-NaF-X)
Trial: 14604742
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg BID
Trial: 14604742
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg BID (adjusted for noncompliance)
Trial: 14604742
Drug: Discontinuing fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuing fluvastatin without switching to another lipid‐lowering medication
Trial: 10685657
Drug: IL-2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 therapy (9 million IU/m2/d for 4 days, then 1.6 million IU/m2/d for 10 days)
Trial: 9514403
Drug: High-dose multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multivitamin supplements containing 5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine
Trial: 9514403
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg folic acid
Trial: 3135934
Drug: Carboplatin in
RxNorm normalized name: Carboplatin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Trial: 3135934
Drug: Cisplatin in
RxNorm normalized name: cisplatin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Trial: 28185997
Drug: Vilaprisan (2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (2mg daily) for 12 or 24 weeks, or two 12-week treatment periods separated by a break to allow one menstruation to occur.
Trial: 28185997
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (5mg daily) for 12 weeks.
Trial: 28185997
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks followed by active treatment for 12 weeks.
Trial: 28185997
Drug: Vilaprisan (2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (2mg daily) in different regimens.
Trial: 26248820
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet medication
Trial: 20221953
Drug: Computerized aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized aphasia treatment
Trial: 20221953
Drug: Phase 3
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 3 study of computerized aphasia treatment
Trial: 18171452
Drug: Open-label conditioned
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label conditioned placebo dose reduction (CPDR) treatment
Trial: 14644721
Drug: Anecortave acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave acetate (15 mg)
Trial: 31386583
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily practice only)
Trial: 15608030
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 20 microg di EE and 150 microg of desogestrel (group B)
Trial: 12200684
Drug: Reinforced courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforced courses of chemotherapy (standard 3+7 including high-dose daunorubicin, double induction, and timed-sequential therapy)
Trial: 12200684
Drug: Reinforced courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforced courses of chemotherapy
Trial: 7572320
Drug: Oral dimethyl-APD
RxNorm normalized name: dimethyl fumarate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dimethyl-APD (100-400 mg/day)
Trial: 7572320
Drug: Intravenous dimethyl-APD
RxNorm normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dimethyl-APD (4 mg/day)
Trial: 2142705
Drug: Early thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early thrombolytic therapy (administered at 7 hours)
Trial: 2142705
Drug: Late thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late thrombolytic therapy (administered at 11 hours)
Trial: 2142705
Drug: Late thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late thrombolytic therapy (administered at 17 hours)
Trial: 2142705
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (timing not specified)
Trial: 508503
Drug: Temazepam 20
RxNorm normalized name: temazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 20 mg (Scherer formulation)
Trial: 508503
Drug: Amylobarbitone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amylobarbitone 100 mg
Trial: 25591053
Drug: Therapeutic Tai
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Tai Chi (10 different movements, 60 min, twice per week, for 6 weeks)
Trial: 22397261
Drug: Intravenous patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient controlled analgesia (PCA) with morphine
Trial: 8405642
Drug: amoxycillin/clavulanate (AMX/CL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxycillin/clavulanate (AMX/CL) 2200 mg i.v. as a single dose
Trial: 8405642
Drug: cefuroxime plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefuroxime plus metronidazole (CR/MN) 750/500 mg i.v. administered 3 times within 24 h
Trial: 30829460
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) - 1 year phoned physical activity advice individually adapted to physical assessment (twice a month during the first 6 months and then monthly)
Trial: 29477692
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN)
Trial: 29477692
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (monthly vs PRN)
Trial: 24456373
Drug: CERA administered
RxNorm normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CERA administered intravenously at weeks 0 and 2 (TWICE group)
Trial: 24456373
Drug: CERA administered
RxNorm normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CERA administered intravenously at week 0 (ONCE group)
Trial: 22156314
Drug: Landiolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (3 µg·kg(‐1)·min(‐1) for 24 h)
Trial: 22156314
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no landiolol administration)
Trial: 20167278
Drug: Defibrotide 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 25 mg/kg/day (arm A)
Trial: 20167278
Drug: Defibrotide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 40 mg/kg/day (arm B)
Trial: 2328959
Drug: Ethanol (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (10% solution in 5% dextrose in water)
Trial: 7016402
Drug: L-valine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-valine (600 mumol/min)
Trial: 7016402
Drug: L-isoleucine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-isoleucine (150 mumol/min)
Trial: 7016402
Drug: L-leucine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-leucine (300 mumol/min)
Trial: 7016402
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of branched-chain amino acids (70% L-leucine, 20% L-valine, 10% L-isoleucine; 270 mumol/min)
Trial: 27862308
Drug: Alemtuzumab consolidation
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab consolidation therapy
Trial: 16267908
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy and local-regional radiotherapy
Trial: 10526275
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with cisplatin plus etoposide (n = 12)
Trial: 10526275
Drug: Concurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent therapy with cisplatin plus etoposide (n = 18)
Trial: 29660295
Drug: Infants' birth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants' birth weight less than 2,300 g
Trial: 12514410
Drug: Atazanavir 200
RxNorm normalized name: atazanavir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 200 mg once daily
Trial: 12514410
Drug: Atazanavir 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 500 mg once daily
Trial: 12514410
Drug: Nelfinavir 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 750 mg three times daily
Trial: 10378564
Drug: MDI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI with small volume spacer (5 puffs, 450 microg albuterol)
Trial: 10378564
Drug: Nebulizer (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer (2.5 mg albuterol)
Trial: 10378564
Drug: MDI port
RxNorm normalized name: My MDI Portable Nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI port on right-angle adaptor (5 puffs, 450 microg albuterol)
Trial: 8686821
Drug: Neostigmine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.04 mg.kg‐1 with atropine 0.02 mg.kg‐1
Trial: 7471605
Drug: Indacrinone (−)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 0 mg (10/0)
Trial: 7471605
Drug: Indacrinone (−)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 10 mg (10/10)
Trial: 7471605
Drug: Indacrinone (−)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 20 mg (10/20)
Trial: 7471605
Drug: Indacrinone (−)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 40 mg (10/40)
Trial: 7471605
Drug: Indacrinone (−)
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone (−) enantiomer 10 mg with (+) enantiomer 80 mg (10/80)
Trial: 7471605
Drug: Ticrynafen (T)
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticrynafen (T) 250 mg daily
Trial: 7471605
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 50 mg daily
Trial: 26860492
Drug: Conventional ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ultrasound therapy for 6 minutes at 1.5 Watt/cm2 dose with 1 MHz frequency for 15 days
Trial: 23320967
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin (500 U/kg, 2 doses, 24 hours apart)
Trial: 19353740
Drug: Debio 025
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 025 600 mg/day + PEG IFN-alpha2a 180 microg/week
Trial: 19353740
Drug: Debio 025
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 025 1000 mg/day + PEG IFN-alpha2a 180 microg/week
Trial: 19353740
Drug: Debio 025
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 025 1000 mg/day (monotherapy)
Trial: 19353740
Drug: PEG IFN-alpha2a
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG IFN-alpha2a 180 microg/week (monotherapy)
Trial: 17868953
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat flavored cream cheese (orange or banana)
Trial: 17868953
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat flavored cream cheese (orange or banana)
Trial: 15497297
Drug: Computer-assisted injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted injection system (Wand Plus)
Trial: 11556573
Drug: HA1 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA1 (500 mg three times daily for 3 days, total dose: 4,500 mg)
Trial: 11556573
Drug: HA2 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA2 (500 mg three times daily for the first and the third day, total dose: 3,000 mg)
Trial: 11556573
Drug: HA3 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA3 (500 mg three times for one day followed by 500 mg once daily for 7 days, total dose: 4,500 mg)
Trial: 9577350
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate 1200 micrograms buccal spray
Trial: 2905188
Drug: Chemotherapy (5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5‐fluorouracil (FU) and 1‐(2‐chloroethyl)‐3‐(4‐methylcyclohexil)‐1‐nitrosourea (Me‐CCNU) after surgery
Trial: 2905188
Drug: Chemo‐immunotherapy (FU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo‐immunotherapy (FU, Me‐CCNU and levamisole) after surgery
Trial: 30753662
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus OH4L (Oral Health 4 Life)
Trial: 23782457
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Trial: 11913275
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 15% hydrogen peroxide in-office treatment and 10% carbamide peroxide take-home treatment
Trial: 9393426
Drug: Spectra-System implants
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectra-System implants (HA-coated cylinders)
Trial: 9393426
Drug: Spectra-System implants
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectra-System implants (titanium alloy baskets)
Trial: 25428762
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly for 8 weeks
Trial: 20580422
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg injected once weekly
Trial: 20580422
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg oral once daily
Trial: 20580422
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg oral once daily
Trial: 18211120
Drug: Dobutamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine at a dose of 2.5 microg/kg/min
Trial: 18211120
Drug: Dobutamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine at a dose of 5 microg/kg/min
Trial: 18211120
Drug: Dobutamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine at a dose of 10 microg/kg/min
Trial: 16630938
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (polymerized extract)
Trial: 28673384
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT) for 24 weeks
Trial: 21143499
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg kg(‐1) ideal body weight
Trial: 21143499
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg kg(‐1) total body weight
Trial: 16550242
Drug: Outpatient family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient family-based therapy (without FMI)
Trial: 10750628
Drug: Functional Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Insulin Treatment (FIT)
Trial: 10780123
Drug: Nicotine transdermal
RxNorm normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine transdermal patch (21 mg)
Trial: 1394752
Drug: Ketorolac (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (1 mg.kg‐1)
Trial: 1394752
Drug: Acetaminophen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (10 mg.kg‐1)
Trial: 1394752
Drug: Saline (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.1 ml.kg‐1)
Trial: 29769831
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g Specific Collagen Peptides (SCP)
Trial: 29769831
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g Placebo (Maltodextrin)
Trial: 22108101
Drug: Vacuum-cast Co-Cr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-cast Co-Cr (CC) with Ketac Cem Plus (KC)
Trial: 22108101
Drug: Vacuum-cast Co-Cr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-cast Co-Cr (CC) with Panavia F 2.0 (PF)
Trial: 22108101
Drug: Vacuum-cast Co-Cr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-cast Co-Cr (CC) with RelyX Unicem 2 Automix (RXU)
Trial: 16089139
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Sodium hyaluronate (SH) plus external application of Sanhua ointment (SHO)
Trial: 16089139
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Sodium hyaluronate (SH)
Trial: 12145036
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (NS) solution
Trial: 2249121
Drug: Cephalosporin antibiotic
RxNorm normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalosporin antibiotic prophylaxis
Trial: 7028069
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with an autologous irradiated suspension of tumour cells combined with a small dose of C. parvum given intradermally during convalescence
Trial: 18551295
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 12 mg lutein and 1 mg zeaxanthin once per day (Ocuvite lutein) for 6 months
Trial: 17645482
Drug: High-dose pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pantoprazole (80 mg + 8 mg/h)
Trial: 17645482
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg q.d.
Trial: 15738857
Drug: Self-help cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help cognitive-behavioral therapy (CBT)
Trial: 11158186
Drug: Nonpeptidic MMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpeptidic MMP inhibitors